{"url_path":"/sec/dmiiu/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2040475/0001213900-26-056651-index.html","accession_number":"0001213900-26-056651","cik":"0002040475","ticker":"DMII","issuer_name":"Drugs Made In America Acquisition II Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2040475/0001213900-26-056651-index.html","primary_entity_key":"0002040475","primary_entity_name":"Drugs Made In America Acquisition II Corp."},"word_count":266,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nThe following exhibits are filed as part of, or incorporated by reference\ninto, this report:\n\n \n\nExhibit No.\n \nDescription\n\n31.1\n \n[Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](ea029002201ex31-1.htm)\n\n31.2\n \n[Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](ea029002201ex31-2.htm)\n\n32.1*\n \n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea029002201ex32-1.htm)\n\n32.2*\n \n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea029002201ex32-2.htm)\n\n101.CAL\n \nXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.SCH\n \nXBRL Taxonomy Extension Schema Document\n\n101.DEF\n \nXBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB\n \nXBRL Taxonomy Extension Labels Linkbase Document\n\n101.PRE\n \nXBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n \nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n*\nFurnished herewith\n\n \n\n23\n\n \n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto\nduly authorized.\n\n \n\nDate: May 14, 2026\nDRUGS MADE IN AMERICA ACQUISITION II CORP.\n\n \n \n\n \nBy:\n/s/ Roger Bendelac\n\n \n \nName: \nRoger Bendelac\n\n \n \nTitle:\nChief Executive Officer\n\n \n \n \n(Principal Executive Officer)\n\n \n \n\n \nBy:\n/s/ Saleem Elmasri\n\n \n \nName:\nSaleem Elmasri\n\n \n \nTitle:\nChief Financial Officer\n\n \n \n \n(Principal Financial and Accounting Officer)\n\n \n\n24"}